NKP-1339 (IT-139; KP-1339) 是一流的基于钌的抗癌剂，正在开发用于治疗实体癌，副作用有限。 NKP-1339 通过线粒体途径诱导 G2/M 细胞周期停滞、DNA 合成阻断和细胞凋亡诱导。 NKP-1339 具有很高的肿瘤靶向潜力，与血清蛋白如白蛋白和转铁蛋白强烈结合，并在还原性肿瘤环境中激活。
| Cas No. | 197723-00-5 |
| 别名 | IT-139; KP-1339 |
| Canonical SMILES | [Cl-][Ru+3]([N]1=CC2=CC=CC=C2N1)([Cl-])([Cl-])([N]3=CC4=CC=CC=C4N3)[Cl-].[Na+] |
| 分子式 | C14H12Cl4N4NaRu |
| 分子量 | 502.14 |
| 溶解度 | DMSO : ≥ 59 mg/mL (117.50 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | NKP-1339(IT-139) is a ruthenium(iii) coordination anticancer compound based on target to transferrin. References:
[1]. Kuhn PS, et al. Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential. Dalton Trans. 2014 Nov 11.
[2]. Robert Trondl, et al. ChemInform Abstract: NKP-1339, the First Ruthenium-Based Anticancer Drug on the Edge to Clinical Application. |
